UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number
333-156480
 
PEAK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260
Telephone: (480) 659-6404
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)
 
☒
Rule 12g-4(a)(2)
 
☒
Rule 12h-3(b)(1)(i)
 
☐
Rule 12h-3(b)(1)(ii)
 
☐
Rule 15d-6
 
☐
 
Approximate number of holders of record as of the certification or notice date: 19
 
 
 
1
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: July 13, 2020
 
 
 
 
PEAK PHARMACEUTICALS, INC.
 
 
By:
 
/s/ Neil Reithinger
Name:
 
Neil Reithinger
Title:
 
Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Peak Pharmaceuticals (PK) Charts.
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Peak Pharmaceuticals (PK) Charts.